+

ES2166001T3 - Utilizacion de compuestos antimineralcorticoides contra el sindrome de abstinencia de narcoticos. - Google Patents

Utilizacion de compuestos antimineralcorticoides contra el sindrome de abstinencia de narcoticos.

Info

Publication number
ES2166001T3
ES2166001T3 ES96931876T ES96931876T ES2166001T3 ES 2166001 T3 ES2166001 T3 ES 2166001T3 ES 96931876 T ES96931876 T ES 96931876T ES 96931876 T ES96931876 T ES 96931876T ES 2166001 T3 ES2166001 T3 ES 2166001T3
Authority
ES
Spain
Prior art keywords
antimineralcorticoid
compounds against
abstinence syndrome
narcotic
narcotic abstinence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96931876T
Other languages
English (en)
Inventor
Francis Petit
Daniel Philibert
Nick Goeders
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of ES2166001T3 publication Critical patent/ES2166001T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A LA APLICACION DE LOS COMPUESTOS QUE TIENEN UNA ACTIVIDAD ANTIMINERALOCORTICOIDE PARA LA ELABORACION DE MEDICAMENTOS DESTINADOS A PREVENIR O TRATAR MANIFESTACIONES LIGADAS A LA DEPENDENCIA O AL SINDROME DE ABSTINENCIA ESPONTANEO O PRECIPITADO PROVOCADO POR LOS NARCOTICOS O MEZCLAS DE NARCOTICOS, Y LOS COMPUESTOS EN CUESTION.
ES96931876T 1995-09-21 1996-09-19 Utilizacion de compuestos antimineralcorticoides contra el sindrome de abstinencia de narcoticos. Expired - Lifetime ES2166001T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9511086A FR2739029B1 (fr) 1995-09-21 1995-09-21 Nouvelle application therapeutique des composes antimineralo-corticoides

Publications (1)

Publication Number Publication Date
ES2166001T3 true ES2166001T3 (es) 2002-04-01

Family

ID=9482793

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96931876T Expired - Lifetime ES2166001T3 (es) 1995-09-21 1996-09-19 Utilizacion de compuestos antimineralcorticoides contra el sindrome de abstinencia de narcoticos.

Country Status (10)

Country Link
US (3) US6147066A (es)
EP (1) EP0863760B1 (es)
JP (1) JP2000513704A (es)
AT (1) ATE209920T1 (es)
DE (1) DE69617729T2 (es)
DK (1) DK0863760T3 (es)
ES (1) ES2166001T3 (es)
FR (1) FR2739029B1 (es)
PT (1) PT863760E (es)
WO (1) WO1997010827A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1726307A3 (en) * 1997-10-06 2007-04-04 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction
ATE332696T1 (de) * 1997-10-06 2006-08-15 Univ Leland Stanford Junior Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
WO2003078394A1 (en) * 2002-03-15 2003-09-25 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
DE102004063864A1 (de) * 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
US8445469B2 (en) * 2004-12-30 2013-05-21 Bayer Intellectual Property Gmbh 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter
US8228301B2 (en) * 2007-07-31 2012-07-24 Kent Displays Incorporated Multiple color writing tablet
US8139039B2 (en) * 2007-07-31 2012-03-20 Kent Displays, Incorporated Selectively erasable electronic writing tablet
US20100265214A1 (en) * 2007-07-31 2010-10-21 Kent Displays Incorporated Writing tablet information recording device
WO2009111574A2 (en) * 2008-03-05 2009-09-11 Evestra, Inc. BISMETHYLENE-17α CARBOLACTONES AND RELATED USES
US9134561B2 (en) 2011-11-01 2015-09-15 Kent Displays Incorporated Writing tablet information recording device
US9235075B2 (en) 2012-05-22 2016-01-12 Kent Displays Incorporated Electronic display with patterned layer
US9116379B2 (en) 2012-05-22 2015-08-25 Kent Displays Incorporated Electronic display with semitransparent back layer
US10088701B2 (en) 2013-11-01 2018-10-02 Kent Displays Inc. Electronic writing device with dot pattern recognition system
US9851612B2 (en) 2014-04-02 2017-12-26 Kent Displays Inc. Liquid crystal display with identifiers
TWI646971B (zh) * 2015-12-04 2019-01-11 鄭恩哲 阻斷海洛因或嗎啡毒品中毒路徑的點滴處方及其應用
SG11201905508VA (en) 2017-01-23 2019-08-27 Regeneron Pharma Hsd17b13 variants and uses thereof
AU2018250727A1 (en) * 2017-04-11 2019-10-31 Regeneron Pharmaceuticals, Inc. Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (HSD17B) family
KR20240125690A (ko) 2017-10-11 2024-08-19 리제너론 파마슈티칼스 인코포레이티드 Pnpla3 i148m 변이를 발현하는 환자의 간 질환의 치료에서의 hsd17b13의 저해

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533517A1 (en) * 1991-08-20 1993-03-24 Chiba Flour Milling Co. Ltd. LPS-containing anti-withdrawal agents
US5869474A (en) * 1997-05-16 1999-02-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Low dosage treatment for cocaine craving and withdrawal

Also Published As

Publication number Publication date
US6147066A (en) 2000-11-14
JP2000513704A (ja) 2000-10-17
WO1997010827A1 (fr) 1997-03-27
US6759399B1 (en) 2004-07-06
DE69617729D1 (de) 2002-01-17
DK0863760T3 (da) 2002-04-02
ATE209920T1 (de) 2001-12-15
FR2739029B1 (fr) 1997-11-21
EP0863760B1 (fr) 2001-12-05
US20040242552A1 (en) 2004-12-02
DE69617729T2 (de) 2002-08-08
EP0863760A1 (fr) 1998-09-16
PT863760E (pt) 2002-05-31
FR2739029A1 (fr) 1997-03-28

Similar Documents

Publication Publication Date Title
ES2166001T3 (es) Utilizacion de compuestos antimineralcorticoides contra el sindrome de abstinencia de narcoticos.
DE69625157D1 (de) Behandlung des typ ii-deabetes mellitus mit amylinagonisten
EA199900168A1 (ru) Применение glp-1 или его аналогов в лечении инфаркта миокарда
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
EA199800626A1 (ru) Применение агониста ppar-гамма для лечения синдрома х
PT880350E (pt) Tratamento de esclerose multipla
EA200101089A1 (ru) Новый способ лечения
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
EA199800866A1 (ru) Способ снятия боли
BR9708525A (pt) Método de tratamento de insuficência cardíaca com antagonistas de endotelina
EA199800535A1 (ru) Способ лечения боли
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
EA199900174A1 (ru) Способ лечения биполярного расстройства
WO1995005364A3 (en) Inhibitors of biogenic amine transporters
EA199800822A1 (ru) Способ лечения избыточной агрессии
DE69831959D1 (de) Verwendung von (E)-metanicotinederivate als Analgetika
MY118982A (en) Method of reducing tissue damage associated with ischemia
EA199800818A1 (ru) Способ лечения бессонницы
MX9800365A (es) Tratamiento de leucemia aguda con interleucina-10.
UA43389C2 (uk) Спосіб зниження рівнів кальцію у сироватці
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами
MX9706404A (es) Metodo para tratar deplecion de adenosina.
NZ505084A (en) Method for treating sexual dysfunctions
EA200101043A1 (ru) Способ лечения неврологических или нейропсихиатрических расстройств

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 863760

Country of ref document: ES

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载